Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

Since its launch, the NovaSeq 6000 Sequencing System has revolutionized genomics studies. Hear how the system has continued to evolve to meet customer demands and shape what’s possible in the future of genomics.

Illumina NGS technology utilizes a fundamentally different approach from the classic Sanger chain-termination method. It leverages sequencing by synthesis (SBS) chemistry – tracking the addition of labeled nucleotides as the DNA chain is copied – in a massively parallel fashion.

Our innovative next-generation sequencing platforms deliver exceptional data quality and accuracy for a range of research needs and scales. In vitro diagnostic instruments* With easy-to-follow workflows and integrated software, our in vitro diagnostic (IVD) instruments deliver accurate, reliable results for diagnostic screening and testing.

The NextSeq 1000 and NextSeq 2000 Systems offer the certainty of a field-tested solution and a reliable sequencing partner. Take advantage of a large ecosystem of applications, protocols, and informatics built in collaboration with thousands of researchers and …

Illumina sequencing technology, sequencing by synthesis, uses fluorescently labeled reversible terminators to detect bases as they’re incorporated into growing DNA strands.

See how the MiSeq i100 Series is setting the standard for simplicity, usability, and speed of benchtop sequencing from Illumina.

The MiniSeq System delivers the power and confidence of proven Illumina next-generation sequencing (NGS) technology in an accessible sequencing solution. The MiniSeq System features: Cost-efficient sequencing, even for low numbers of samples

MiSeq System is a benchtop sequencing system capable of performing a broad range of sequencing applications. Optimized sample preparation kits, push-button operation, and automated data analysis create a fast and easy end-to-end sequencing workflow for any lab.

As next-generation sequencing costs continue to decline, Illumina is leading the way in making NGS more affordable and accessible through continuous innovation. There has been a 96% decrease in the average cost-per-genome since 20131,2.